Drug Type Biosimilar, Monoclonal antibody |
Synonyms Ustekinumab Biosimilar (Reliance Life Sciences Pvt Ltd.), ustekinumab biosimilar (Reliance Life Sciences), R TPR 046 + [1] |
Target |
Action inhibitors |
Mechanism IL-12 inhibitors(Interleukin-12 inhibitors), IL-23 inhibitors(Interleukin-23 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 3 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Plaque psoriasis | Phase 3 | India | 11 Sep 2020 |